Lamotrigine (All indications)

Emotional disorders

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15229
R62521
Dreier (Lamotrigine) (Epilepsy) (Controls unexposed, sick), 2023 Anxiety disorder - Corresponding ICD-10 F-chapter - Up to 22 years of age during pregnancy (anytime or not specified) population based cohort propective unexposed, sick Adjustment: Yes 1.01 [0.80;1.27] 97/5,288   458/22,203 555 5,288
ref
S8941
R30230
Cohen-Israel (Lamotrigine), 2018 Emotional disturbance (a majority between 6-12 years old) 1st trimester retrospective cohort unexposed, disease free Adjustment: No Matched 5.12 [0.24;108.41] C 2/83   0/83 2 83
ref
Total 2 studies 1.08 [0.57;2.07] 557 5,371
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Dreier (Lamotrigine) (Epilepsy) (Controls unexposed, sick), 2023Dreier, 2023 1 1.01[0.80; 1.27]5555,28896%ROB confusion: seriousROB selection: lowROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Cohen-Israel (Lamotrigine), 2018Cohen-Israel, 2018 2 5.12[0.24; 108.41]2834%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Total (2 studies) I2 = 8% 1.08[0.57; 2.07]5575,3710.520.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Lamotrigine) (Epilepsy) (Controls unexposed, sick; 2: Lamotrigine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.08[0.57; 2.07]5575,3718%NADreier (Lamotrigine) (Epilepsy) (Controls unexposed, sick), 2023 Cohen-Israel (Lamotrigine), 2018 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 5.12[0.24; 108.41]283 -NACohen-Israel (Lamotrigine), 2018 1 unexposed, sickunexposed, sick 1.01[0.80; 1.27]5555,288 -NADreier (Lamotrigine) (Epilepsy) (Controls unexposed, sick), 2023 1 Tags Adjustment   - No  - No 5.12[0.24; 108.41]283 -NACohen-Israel (Lamotrigine), 2018 1   - Yes  - Yes 1.01[0.80; 1.27]5555,288 -NADreier (Lamotrigine) (Epilepsy) (Controls unexposed, sick), 2023 1 MatchedMatched 5.12[0.24; 108.41]283 -NACohen-Israel (Lamotrigine), 2018 1 All studiesAll studies 1.08[0.57; 2.07]5575,3718%NADreier (Lamotrigine) (Epilepsy) (Controls unexposed, sick), 2023 Cohen-Israel (Lamotrigine), 2018 20.520.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 5.12[0.24; 108.41]283 -NACohen-Israel (Lamotrigine), 2018 1 unexposed, sick controlsunexposed, sick controls 1.01[0.80; 1.27]5555,288 -NADreier (Lamotrigine) (Epilepsy) (Controls unexposed, sick), 2023 10.510.01.0